We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-19.92%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$458M
AUM Growth
-$75M
Cap. Flow
+$97.5M
Cap. Flow %
21.29%
Top 10 Hldgs %
83.75%
Holding
19
New
2
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$89M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.68M
3
COGT icon
Cogent Biosciences
COGT
+$4.95M

Top Sells

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEAR
1
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$94.1M 20.55%
18,631,771
– –
CINC
2
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$76.1M 16.62%
+4,337,646
New +$89M
TRDA icon
3
Entrada Therapeutics
TRDA
$282M
$41.4M 9.04%
4,408,379
– –
VOR icon
4
Vor Biopharma
VOR
$1.16B
$38.4M 8.39%
318,086
– –
RLYB icon
5
Rallybio
RLYB
$84.6M
$27.8M 6.07%
497,591
-26,250
-5% -$2.17M
ARVN icon
6
Arvinas
ARVN
$520M
$26.9M 5.88%
400,000
– –
SCPH
7
DELISTED
scPharmaceuticals
SCPH
$21.8M 4.75%
3,831,474
– –
AKUS
8
DELISTED
Akouos Inc
AKUS
$19.6M 4.29%
4,135,784
– –
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.89B
$18.9M 4.13%
862,286
– –
IMPL
10
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$18.4M 4.01%
2,884,791
– –
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.3M 3.78%
1,027,874
+384,626
+60% +$5.68M
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.41B
$15.6M 3.42%
1,398,066
– –
QTTB icon
13
Q32 Bio
QTTB
$450M
$13.8M 3.01%
251,996
– –
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$7.21M 1.58%
390,555
– –
JANX icon
15
Janux Therapeutics
JANX
$934M
$6.4M 1.4%
446,266
– –
COGT icon
16
Cogent Biosciences
COGT
$6.64B
$5.33M 1.16%
+711,412
New +$4.95M
CABA icon
17
Cabaletta Bio
CABA
$439M
$4.19M 0.92%
2,064,263
– –
FVAM
18
DELISTED
5:01 Acquisition Corp
FVAM
$3.6M 0.79%
365,126
– –
CDTX
19
DELISTED
Cidara Therapeutics
CDTX
$945K 0.21%
56,726
– –

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q1 2022 Portfolio in Review

As of Q1 2022, 5AM Venture Management held 19 positions worth $458M, down 14% from $533M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

5AM Venture Management deployed $97.5M of net new capital in Q1 2022, opening 2 new positions and adding to 1 existing holding. Its largest new stake was CinCor Pharma, Inc. Common Stock: 4,337,646 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Rallybio, an estimated $2.17M trimmed.

  • 5AM Venture Management's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 4,337,646 shares worth $76.1M.
  • 5AM Venture Management added most to IVERIC bio, Inc. Common Stock in Q1 2022, an estimated $5.68M increase.
  • 5AM Venture Management's biggest Q1 2022 reduction was Rallybio, cutting an estimated $2.17M.
  • 5AM Venture Management's ten largest holdings make up 84% of its $458M portfolio in Q1 2022.
  • 5AM Venture Management opened 2 new positions and closed 0 in Q1 2022.
  • 5AM Venture Management's portfolio value fell 14% quarter-over-quarter to $458M.

Based on 5AM Venture Management's 13F filing for Q1 2022, filed 16 May 2022.